Tirzepatide explained: the dual-agonist behind Mounjaro and Zepbound

Tirzepatide is the first medication in its class — a single molecule that activates two different incretin receptors at once. The first is GLP-1 (the same receptor semaglutide targets). The second is GIP, glucose-dependent insulinotropic polypeptide, another gut hormone released after meals. Both are members of the broader incretin family, both have effects on insulin secretion and appetite, and both are released in response to food.

The bet that tirzepatide is built on is straightforward: if activating GLP-1 alone produces meaningful weight loss, activating GLP-1 and GIP together should produce more. The trial results so far suggest that bet has paid off.

Eli Lilly developed tirzepatide and brought it to market as Mounjaro in 2022 (FDA-approved for type 2 diabetes) and Zepbound in late 2023 (approved for chronic weight management). Like Ozempic and Wegovy, the active ingredient is identical between the two brands — the indication, dose ceiling, and packaging differ.

GIP has had a strange history in obesity research. Early animal studies suggested that blocking GIP, not activating it, would help with weight loss — knockout mice without GIP receptors were resistant to diet-induced obesity. So when Lilly began developing a GIP-activating agent, many researchers were skeptical.

The clinical data flipped that picture. In humans, activating GIP alongside GLP-1 appears to produce additive effects on appetite suppression and improved insulin sensitivity, especially in fat tissue. The current best understanding is that GIP signaling in the central nervous system contributes to satiety, and that GIP signaling in adipose tissue helps the body handle the fat-storage and lipid-metabolism side of weight regulation.

There is also a hypothesis that GIP receptor activation in the brain may reduce some of the nausea associated with GLP-1 alone — meaning some patients tolerate tirzepatide a bit better than they tolerated semaglutide, even at comparable weight-loss effect. The data on this is still soft, but the patient reports are consistent enough that it is worth mentioning.

SURMOUNT-1, published in 2022, randomized 2,539 adults with obesity (BMI ≥30) or with overweight and at least one weight-related condition, but without diabetes. Participants received tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks alongside lifestyle counseling. Average weight reductions were 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% on placebo. Nine in ten patients on the highest dose lost at least 5% of body weight; about half lost at least 20%.

SURMOUNT-2 looked at adults with type 2 diabetes and obesity, where weight loss tends to be harder to achieve. Tirzepatide produced average reductions of 12.8% at 10 mg and 14.7% at 15 mg over 72 weeks — still well above what is typically seen with other agents in patients with diabetes.

SURMOUNT-3 used a lifestyle intervention as a lead-in, then introduced tirzepatide for patients who had already lost some weight, and showed continued substantial loss. SURMOUNT-4 looked at the question of what happens if you withdraw tirzepatide after a year — the answer was rapid regain, mirroring what semaglutide trials have shown.

A separate study — SURPASS-2, in patients with type 2 diabetes — compared tirzepatide directly to semaglutide. Tirzepatide outperformed semaglutide on both A1c reduction and weight loss across all three dose levels tested. It is currently the strongest pharmacologic intervention available for the type 2 diabetes plus obesity population.

Trial numbers favor tirzepatide for weight loss in non-diabetic adults: roughly 20% versus roughly 15% on the highest doses of each. That is meaningful — a 5-percentage-point difference at scale corresponds to several pounds of additional loss for most patients. SURPASS-2 also showed a clear advantage in patients with diabetes, where tirzepatide produced larger reductions in both A1c and weight than semaglutide.

In practice, the difference for any individual patient is harder to predict. Some patients respond better to semaglutide, some to tirzepatide, and the only way to know is to try. The mechanisms overlap but are not identical, and individual variation in how the medications are metabolized and how the receptors respond is genuine.

Cost and access also vary. At the time of writing, both medications are widely available, but Mounjaro and Zepbound have at points been in shortage as demand outstripped supply. Insurance coverage for the weight-management indications (Wegovy, Zepbound) is inconsistent and tends to require prior authorization. Many patients have ended up on whichever medication their insurance approved first or whichever was in stock at their local pharmacy — pragmatism wins.

Compounded versions of both medications became widely available during the FDA-declared shortages, then became much less available as the shortages were resolved and the FDA tightened compounding rules. The compounding question is its own conversation; the short version is that branded products are the cleanest path when you can access them.

Tirzepatide is dosed once weekly by subcutaneous injection, the same way semaglutide is. The starting dose is 2.5 mg weekly for four weeks. This is the tolerance-building step and is not expected to produce significant weight loss on its own.

After the starter, the dose increases by 2.5 mg every four weeks: to 5 mg, then 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg as the maximum maintenance dose. Patients can hold at a lower dose (commonly 5, 10, or 15 mg) if it is producing acceptable results. The 7.5 and 12.5 mg doses are intermediate steps and are not typical maintenance doses.

Like semaglutide, the titration is the most fragile part of the protocol — moving too fast almost always means worse nausea and a higher dropout risk. Patience pays off.

The injection is delivered via a single-use auto-injector pen. Patients pick a consistent day of the week, rotate sites among abdomen, thigh, and upper arm, and store the pens refrigerated until use. Missed-dose guidance is similar to semaglutide: take within four days of the scheduled day; otherwise skip and resume.

The side effect profile is broadly similar to semaglutide — gastrointestinal symptoms dominate. In SURMOUNT-1, nausea was reported by roughly 30% of patients, diarrhea by about 20%, constipation by about 15%, and vomiting by about 10%. Most events were mild to moderate and most resolved with continued treatment.

Some patients report that tirzepatide is slightly easier on the stomach than semaglutide at comparable weight-loss effect, possibly related to the GIP component. This is anecdotally common but not yet definitively shown in head-to-head trials.

The serious side effects parallel the semaglutide list: pancreatitis, gallbladder disease, and rare bowel obstruction. The class warning for medullary thyroid carcinoma applies here too — tirzepatide is contraindicated in patients with a personal or family history of MTC or MEN2.

A specific point worth flagging: tirzepatide may reduce the effectiveness of oral contraceptives, particularly during dose escalation. Patients on oral birth control are often advised to switch to a non-oral method or use a backup method during the first weeks after each dose increase.

Tirzepatide is approved for the same general population as semaglutide for weight management: adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. For adults with type 2 diabetes who also need weight loss, the trial data make a strong case for tirzepatide as the first-line option.

For patients without diabetes who are deciding between semaglutide and tirzepatide on weight effect alone, the choice is reasonable to make based on cost, insurance coverage, and clinician availability. The headline-numbers difference between the two is real but not decisive — both are dramatically more effective than anything that came before.

Patients with a strong personal preference for the slightly stronger trial data, those who did not get adequate results on semaglutide, and those for whom GLP-1 alone produced too much nausea may all reasonably choose tirzepatide. Patients who have had trouble accessing tirzepatide due to supply or insurance may reasonably default to semaglutide.

The honest framing: this is a class of medications, not a horse race. Either medication, used consistently as part of a long-term plan that includes nutrition and resistance training, will produce substantially better outcomes than no medication at all. The marginal difference between them matters less than the difference between being on either one and being on neither.

Tirzepatide list pricing in the United States in 2026 is in the same broad range as semaglutide — roughly $1,000 to $1,300 per month at cash list price, with significant variation by pharmacy and savings program. Like Wegovy, Zepbound is sometimes covered by commercial insurance under an obesity benefit, and like Wegovy, the path to coverage typically runs through a prior authorization that requires documentation of BMI, weight-related conditions, and prior weight-loss attempts.

Mounjaro (the diabetes-indication brand) is more often covered by commercial insurance because diabetes coverage is broader than obesity coverage in most U.S. plans. This is part of why some patients with both diabetes and obesity end up on Mounjaro for the practical reason that it is what their insurance will pay for, even though the molecule and dose may be identical to Zepbound.

Eli Lilly offers a manufacturer savings program for commercially insured patients without coverage that can substantially lower the cash cost. Patient assistance programs exist for patients meeting income thresholds, though as with most drug-manufacturer assistance programs, the application process is involved and the eligibility criteria are strict.

The compounding question is the messier part of the access landscape. During the FDA-recognized shortage of tirzepatide that ran through much of 2023 and 2024, compounding pharmacies were temporarily allowed to produce compounded tirzepatide for individual patients. Compounded tirzepatide became widely available through telehealth platforms at a fraction of the branded price, and tens of thousands of patients accessed the medication this way during the shortage period.

In late 2024, the FDA declared the tirzepatide shortage resolved and began enforcement actions against compounding pharmacies producing the medication. The legal availability of compounded tirzepatide collapsed in the months that followed, and most patients who had been getting compounded versions had to transition either to the branded products or off the medication entirely.

As of 2026, the cleanest legal path to tirzepatide for U.S. patients is one of the branded products — Mounjaro for diabetes, Zepbound for weight management. Compounded versions still exist in narrow circumstances (specific allergies, FDA-recognized localized shortages, custom dosing for documented medical needs) but are no longer the broad access channel they were two years ago. Patients still being offered compounded tirzepatide through telehealth platforms in 2026 should ask carefully about the legal basis for the compounding, the quality controls on the compounded product, and what the plan would be if the compounding pharmacy were to be shut down by FDA enforcement.

The honest summary: branded is the safer, cleaner path when you can access it. Compounded was a useful workaround during the 2023–2024 shortage and is much harder to recommend in 2026 unless you have a specific medical reason that the compounded version is the only fit for your situation.

Worth flagging for any patient comparing options: the difference between paying full cash list price for branded tirzepatide and getting the same active ingredient through a covered insurance benefit can be more than $1,000 per month. That is large enough that it changes who can realistically stay on the medication for the multi-year period the trial data is built on. The single most useful thing you can do before scheduling a discovery visit with a prescriber is call your insurance and ask, in plain language: "Do you cover Zepbound for chronic weight management, and if so, what does the prior authorization process require from my clinician?" The answer determines a lot of the downstream conversation, and it is one of the few cost questions that has a definitive answer rather than a hedged one.